Undisclosed Tau Degrader
Neurodegeneration
Lead IDActive
Key Facts
About Seed Therapeutics
SEED Therapeutics is a private, pre-revenue biotech developing a next-generation platform for molecular glue degraders. Its core innovation, the RITE3™ platform, seeks to unlock the full universe of over 600 human E3 ligases to rationally degrade disease proteins considered 'undruggable' by traditional modalities. The company has a lead oncology asset, ST-01156, in Phase 1 trials and a pipeline of partnered and internal programs, backed by a scientifically distinguished founding team including Nobel Laureate Avram Hershko. SEED represents a high-potential, high-risk venture aiming to expand the reach of targeted protein degradation beyond the current limitations of the field.
View full company profileTherapeutic Areas
Other Neurodegeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | Junevity | Pre-clinical |
| Undisclosed Program(s) | 4M Therapeutics | Pre-clinical |
| Undisclosed Program | Wayfinder Biosciences | Target ID/Discovery |